Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 12/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201416 | 0.86 | TRPA1 (0.47) | TRPA1ESR1ESR2NOS3NOS1 | |
| SCHEMBL16230320 | 0.82 | ESR1 (0.38) | ESR1ESR2HSP90AA1 | |
| SCHEMBL1099641 | 0.82 | ESR1 (0.38) | ESR1ESR2HSP90AA1 | |
| SCHEMBL8185278 | 0.80 | EDNRB (0.43) | TRPA1ESR1ESR2KIF11NPC1 | |
| SCHEMBL12012754 | 0.79 | NOS3 (0.39) | TRPA1NOS3NOS1NOS2KIF11 | |
| SCHEMBL20883957 | 0.76 | TSHR (0.35) | TRPA1ESR1ESR2KIF11ELANE | |
| SCHEMBL1101176 | 0.76 | ESR1 (0.45) | TRPA1ESR1ESR2HSP90AA1NPC1 | |
| SCHEMBL2137945 | 0.75 | ESR1 (0.61) | ESR1ESR2HSP90AA1SMN1; SMN2 | |
| SCHEMBL8290795 | 0.72 | ESR1 (0.41) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5514251 | 0.72 | ACHE (0.41) | ESR1ESR2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153816-B2 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-OXO-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20110263866-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-OXO-2-SUBSTITUTED-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-8017789-B2 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-OXO-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl]methoxy]phenyl]proprionate ester and intermediate for the process | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090099369-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-OXO-2-SUBSTITUTED-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | TRPA1 4672/4885ESR1 4351/4885ESR2 3556/4885 |
| US-20090099369-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-OXO-2-SUBSTITUTED-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | HPD, HAO2, HAAO | TRPA1 2216/4885ESR1 4464/4885ESR2 2828/4885 |
| US-20110263866-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-OXO-2-SUBSTITUTED-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | CYP3A4, HPD, POR | TRPA1 1867/4885ESR1 4077/4885ESR2 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.